|Bid||297.50 x 800|
|Ask||297.56 x 800|
|Day's Range||283.50 - 300.50|
|52 Week Range||118.55 - 388.97|
|Beta (5Y Monthly)||0.86|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Market forces rained on the parade of BeiGene, Ltd. ( NASDAQ:BGNE ) shareholders today, when the analysts downgraded...
Assembly Biosciences Inc (NASDAQ: ASMB) will not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy (CST), as the company wants to focus on hepatitis B therapies. The CST study was supposed to be conducted with BeiGene Ltd (NASDAQ: BGNE), which licensed the rights to VBR in China. The company will prioritize its portfolio of next-generation core inhibitors and combinations of VBR with complementary action mechanisms and plans to advance multiple research programs and new mechanisms to human trials. By redirecting the resources previously reserved for the CST, the company sees the cash runway extended into 2023, compared to the second half of 2022, expected earlier. Assembly Bio's HBV pipeline includes three clinical-stage core inhibitor candidates and multiple research and discovery programs. Two clinical studies are underway, with one more study expected to begin during the first half of 2021. In December, the company closed its microbiome program to prioritize resources and focus on advancing its core inhibitors for chronic HBV. Assembly Bio reported disappointing results from a Phase 2 study evaluating vebicorvir in treating chronic hepatitis B virus infection patients. The study failed to achieve meaningful, sustained virologic response rates as 39 of 41 patients relapsed. Price Action: ASMB is up 1.6% at $5.62 in premarket trading on the last check Friday, while BGNE closed 1.5% lower at $329.7 on Thursday. See more from BenzingaClick here for options trades from BenzingaBeiGene's US Application For BRUKINSA In A Type Of Lymphoma, Accepted For Review© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application seeking approval for BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström's Macroglobulinemia (WM), a type of blood cancer. The target Action date is set for October 18. In November 2019, BRUKINSA received accelerated approval in the U.S. to treat mantle cell lymphoma in adult patients who have received at least one prior therapy. In June 2020, BRUKINSA received conditional approval in China as a treatment for adult patients with chronic lymphocytic leukemia /small lymphocytic lymphoma who have received at least one prior therapy and as a treatment for adult patients with mantle cell lymphoma who have received at least one prior therapy. Price Action: BGNE shares are down 0.55% at $381.83 on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaNektar Therapeutics Secures 0M From SFJ Pharma For New Study With BEMPEG/Pembrolizumab Combo In Head & Neck CancerEli Lilly's Tirzepatide Reduces A1C And Body Weight, Late-Stage Studies In Type 2 Diabetes Show© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.